Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

Regeneron (REGN) stock drops as the company's Q1 2025 results miss forecasts amid disappointing sales from its blockbuster ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS (a) of $8.22; First quarter 2025 Dupixent ® global net sales (recorded by Sanofi) ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The European Commission has become the first regulator worldwide to approve Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease ...

Sanofi's Dupixent gets FDA nod for chronic hives indication Dupixent's seventh indication is chronic hives, where a new treatment hasn't been approved since Novartis's Xolair in 2014 Sales & Marketing ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 14,447.11 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...